Dewpoint Therapeutics’ Post

Exciting news from Dewpoint Therapeutics! We’re partnering with Mitsubishi Tanabe Pharma Corporation (MTPC) to advance a groundbreaking small molecule condensate modulator (c-mod) targeting TDP-43 mislocalization, a key pathology in ~97% of ALS patients. I’m proud of the innovative work from our team that brought us to this milestone and hopeful for the difference this could make for ALS patients around the world. Learn more: https://lnkd.in/ghWguxv5 #ALS #CondensateScience #Innovation #Partnership

64Cu-177Lu-DOTATATE is a theranostic radiopharmaceutical used in nuclear medicine for the diagnosis and treatment of neuroendocrine tumors (NETs). It combines the diagnostic properties of 64Cu and the therapeutic properties of 177Lu with the targeting molecule DOTATATE, which binds to somatostatin receptors commonly found on NET cells. This approach allows for both imaging and treatment of tumors, offering a personalized medicine option for patients with NETs. We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time. #64Cu-#177Lu-#DOTATATE #theranostic #radiopharmaceutical #targeting #molecule #imaging and #treatment of #tumors #kg #level #cost#effective https://lnkd.in/gv75v82Y

Orbit Discovery and Evergreen Theragnostics have extended their research collaboration to develop novel targeting peptides for radiopharmaceutical delivery. This partnership builds on a previous agreement and combines Orbit's peptide discovery platform with Evergreen's expertise in radiopharmaceuticals

PanMediso Spotlight｜Potential Applications of Supramolecular Chemistry in Cancer Diagnostics and Radiopharmaceuticals Supramolecular chemistry shows great potential in cancer treatment and diagnosis, with its material systems capable of rapid generation through self-assembly, flexible chemical synthesis, and reversible non-covalent interactions. On October 28, 2024, Guillermo Moreno-Alcántar, Angela Casini, and others from the Technical University of Munich (Technische Universität München) published a review in Nature Reviews Chemistry. This review focuses on the application advancements of self-assembled complexes and mechanically interlocked molecules, such as metal-organic cages and rotaxanes, as well as in situ-formed supramolecular aggregates in radiopharmaceuticals, emphasizing their potential as the next generation of radiopharmaceutical agents. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #NatureReviewsChemistry  #Radiopharmaceuticals #CancerTreatment #Diagnosis

PanMediso Spotlight｜Peking University and Changping Laboratory Make Major Advances in Radiopharmaceuticals The team led by Liu Zhibo at Peking University and Changping Laboratory has developed an innovative Covalent Targeted Radioligand (CTR), a new type of radiopharmaceutical. This innovation overcomes the traditional challenge of balancing "rapid clearance" and "long retention" in radiopharmaceuticals. CTR has demonstrated its effectiveness at the molecular, cellular, mouse, and patient levels, and has shown higher tumor imaging sensitivity in clinical studies compared to traditional methods, making it a promising candidate for the next generation of more effective radiopharmaceuticals. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #PekingUniversity #ChangpingLaboratory #radiopharmaceuticals #Radioligand

"G-protein-coupled receptors (GPCRs) are seven-transmembrane receptors that play critical roles in mediating cellular responses. Within the class A #GPCR family, the μ-opioid receptor (MOR) has garnered considerable interest due to its central role in analgesia and its susceptibility to opioid analgesics such as morphine. Potential modulation of MOR function presents an avenue towards distinct #Analgesics that could avoid the issues associated with current opioid treatments such as dependency, tolerance, and constipation. BMS-986122 stands out as a subtype-selective allosteric modulator of MOR, capable of enhancing endogenous opioid peptide pathways. Interestingly, #Allosteric modulator have been shown to enhance GPCR activation beyond what is achievable by orthosteric agonists alone. Although there are examples that have studied the mechanism of allosteric modulation of GPCRs using in silico approaches, the structural basis underlying the activity enhancement by the allosteric modulators remains incompletely understood!" In this fantastic open-access article published in Nature Portfolio Communications last week, Ichio Shimada and colleagues from RIKEN, The University of Tokyo and Hiroshima University revealed the #CryoEM structure of MOR in complex with its Gi protein, the orthosteric agonist DAMGO and the allosteric modulator BMS-986122: https://lnkd.in/eqX_nFuY Combining these structural findings with nuclear magnetic resonance (NMR) spectroscopy information, presents an attractive strategy for #DrugDevelopment of novel therapeutics enabling the full activation of GPCRs such as MOR!

#Radiopharmaceutical_Nuclear_Medicine Market Share Expands with Rising Demand for Targeted Cancer Treatments >> https://lnkd.in/euQS78RQ #Radiopharmaceutical/nuclear #medicine refers to a radioactive drug used for monitoring and treating #patients suffering from #cancer, heart related problems, and neural #issues. The trace amount of #radioisotope present in the medicine #binds the organic compound, which is later conveyed, to the target cell, #tissue or organ. The rays emitted by radioisotope are detected by specific #imaging device. Eckert & Ziegler SE Mallinckrodt Pharmaceuticals GE HealthCare Jubilant Life Sciences (USA) Inc. Nordion Bracco Imaging Korea Nuclear Science User Facilities (NSUF) NTP Eczacıbaşı-Monrol Nuclear Products Lantheus Medical Imaging IncLantheus MI Australia Pty Ltd Cardinal Health #healthcareindustry #pharmaceuticalindustry #healthcareresearch #biotechnology #Radiopharmaceutical #nuclearmedicine #radioactive  

#Avion will be at #EANM The Avion team are excited to be attending the EANM Congress in Hamburg (19-23 Oct) – it is an incredible opportunity to catch up with colleagues and partners helping to shape this diverse, exciting, and ever-growing specialty of nuclear medicine. Avion is a full-service CRO and research imaging specialist with niche expertise in radiopharmaceutical research. We have the knowledge and capabilities to provide end-to-end support for nuclear medicine clinical trials and medical research, and manage every stage of the research process. What sets us apart? Avion understands the unique challenges of radiopharmaceutical research, and can provide solutions driven by the latest knowledge and expertise to ensure successful completion of theranostic projects. Like to know more? Book a meeting during EANM with Dr Sam Vohra and Jerome Barley… email info@avionmedical.com.au #avion #avionmedical #avioncro #cro #icro #contractresearchorganisation #researchimaging #ClinicalTrials #MedicalResearch #PharmaInnovation #LifeSciences #Biotech #Pharmaceuticals #PrecisionMedicine #RegulatoryAffairs #PatientSafety #DataManagement #DrugDevelopment #ResearchExcellence #Therapeutics

Low-energy electrons (Auger electrons) can be produced via the interaction of photons with gold atoms in gold #nanorods (AuNRs). These electrons are similar to those emitted during the decay of technetium-99m (99mTc), a radioactive nuclide widely used for diagnostics in #nuclear medicine. Auger and internal conversion (IC) electron emitters appropriately targeted to the DNA of tumors cells may, therefore, represent a new radiotherapeutic approach. 99mTc #radiopharmaceuticals, which are used for diagnosis, could indeed be used in theragnostic fields when loaded on AuNRs and delivered to a tumor site. This work aims to provide a proof of concept (i) to evaluate AuNRs as carriers of 99mTc-based radiopharmaceuticals, and (ii) to evaluate the efficacy of Auger electrons emitted by photon-irradiated AuNRs in inducing radio-induced damage in T98G cells, thus mimicking the effect of Auger electrons emitted during the decay of 99mTc used in clinical settings.